Electromed, Inc. $ELMD Position Increased by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. boosted its position in shares of Electromed, Inc. (NYSE:ELMD) by 9.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 32,281 shares of the company’s stock after purchasing an additional 2,672 shares during the period. Goldman Sachs Group Inc. owned 0.38% of Electromed worth $770,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. State of Wyoming purchased a new stake in shares of Electromed during the 1st quarter worth about $48,000. Bank of America Corp DE raised its position in Electromed by 179.2% during the fourth quarter. Bank of America Corp DE now owns 4,004 shares of the company’s stock valued at $118,000 after acquiring an additional 2,570 shares in the last quarter. Quantbot Technologies LP lifted its stake in Electromed by 57.7% in the first quarter. Quantbot Technologies LP now owns 5,301 shares of the company’s stock valued at $126,000 after acquiring an additional 1,939 shares during the last quarter. Two Sigma Advisers LP acquired a new stake in Electromed in the fourth quarter valued at approximately $219,000. Finally, Russell Investments Group Ltd. grew its position in Electromed by 557.0% in the first quarter. Russell Investments Group Ltd. now owns 7,969 shares of the company’s stock worth $186,000 after acquiring an additional 6,756 shares in the last quarter. 40.82% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Electromed

In related news, Director Andrew Summers sold 62,561 shares of the firm’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $24.32, for a total value of $1,521,483.52. Following the completion of the transaction, the director directly owned 3,153 shares of the company’s stock, valued at $76,680.96. This trade represents a 95.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 14.00% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on ELMD. Loop Capital set a $36.00 price target on shares of Electromed in a report on Wednesday, August 27th. Lake Street Capital initiated coverage on Electromed in a report on Wednesday, August 27th. They set a “buy” rating and a $36.00 target price on the stock. Finally, Roth Capital boosted their price target on Electromed from $29.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, August 27th. One analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $36.25.

Electromed Stock Down 4.0%

Electromed stock opened at $23.88 on Wednesday. The business has a 50 day moving average price of $21.22 and a two-hundred day moving average price of $21.72. Electromed, Inc. has a 12 month low of $17.73 and a 12 month high of $35.56. The stock has a market cap of $199.37 million, a price-to-earnings ratio of 31.84 and a beta of 0.54.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.